Join us for a fascinating conversation with Dr. Subhoja Chakraborty from the University of Central Florida, whose cutting-edge research targets the global challenge of malaria drug resistance. Dr. Chakraborty shares her journey from structure-based drug design during her PhD to her recent collaborative work repurposing human kinase inhibitors as rapid, selective antimalarials against drug-resistant Plasmodium falciparum strains.<h4>In this episode, you'll learn:</h4><ul><li>How structure-guided approaches reveal potential drug targets, including cysteine proteases like falcipain-2, and kinases implicated in malaria's complex life cycle.</li><li>The power of repurposing kinase inhibitors originally developed for cancer and other diseases, focusing on compound 12, which blocks hemozoin formation and protein kinase 6—key steps in parasite survival.</li><li>Lab techniques such as affinity, gel filtration, and size exclusion chromatography for recombinant protein purification—and how troubleshooting is crucial for high-yield, stable complexes.</li><li>Advances in mass spectrometry for characterizing protein interactions, validating drug targets, and mapping molecular pathways pivotal to malaria therapeutics.</li><li>Tips and lessons for new researchers facing the challenges of sample preparation, complex protocols, and working as part of a collaborative team.</li></ul>Dr. Chakraborty’s insights bridge the gap between basic science and translational drug discovery, offering hope for more effective, targeted malaria treatments in a world where resistance to frontline therapies threatens millions.<h4>Referenced Papers:</h4><ul><li>"Plasmodium falciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity" (Cell Chemical Biology, 2025)</li><li>"New insights of falcipain 2 structure from Plasmodium falciparum 3D7 strain" (BBRC, 2022)</li><li>"Structure-Based Optimization of Protease−Inhibitor Interactions to Enhance Specificity of Human Stefin‑A against Falcipain‑2 from the Plasmodium falciparum 3D7 Strain" (Biochemistry, 2023)</li></ul>If you’re a student, scientist, or simply passionate about advances in infectious disease research, this episode offers actionable insights, inspiring advice, and a front-row seat to innovation in combating malaria.<h3>Video Transcription</h3><h4>From Structural Biology to Drug Discovery: Chromatography and Mass Spectrometry in Malaria Research</h4><h5>Introduction</h5>In this discussion, Subhoja shares insights into her research journey, focusing on malaria drug discovery and the role of modern analytical techniques in biological and biomedical research. The conversation is aimed primarily at undergraduate students and early-career researchers interested in chemistry, biotechnology, and life sciences.<h5>Research Focus: Malaria Drug Discovery and Kinase Targets</h5>Subhoja is currently involved in malaria drug discovery research at the University of Central Florida, where she has been working since beginning her postdoctoral position two years ago. Her earlier PhD research focused on structure-based drug design in malaria, using a combination of in silico approaches, recombinant protein expression, and X-ray crystallography to determine precise three-dimensional structures of target proteins and their inhibitors.This structural perspective provided a foundation for her current work, which centers on drug discovery through compound screening and repurposing. A recent publication from her laboratory explores the use of repurposed mammalian CDK-like kinase inhibitors as potential antimalarial agents. While such kinase inhibitors are well known in cancer and cardiovascular research, their application to malaria targets represents a novel and promising approach.Kinases are attractive drug targets because of their central role in cell signaling and growth pathways. By targeting specific kinases involved in different stages of the malaria parasite life cycle—whether asexual growth, gametocytogenesis, or differentiation—it may be possible to significantly inhibit parasite growth and progression.<h5>Chromatography in Protein Expression and Purification Workflows</h5>Chromatography plays a critical role throughout Subhoja’s research. Her experience spans from basic chromatography techniques during her early training to advanced protein purification workflows using affinity chromatography, gel filtration (size exclusion chromatography), and ion exchange chromatography.Recombinant proteins are routinely purified using affinity resins such as nickel or cobalt, followed by further purification to remove contaminants. Fast Protein Liquid Chromatography (FPLC) enables compact, stepwise purification workflows suitable for producing proteins for in vitro assays.A recurring challenge in this process is the expression of high-molecular-weight proteins, which often accumulate in insoluble fractions or inclusion bodies. Careful selection of expression vectors, host systems, and induction conditions is therefore essential to maximize yield and solubility.<h5>Integrating Size Exclusion Chromatography into the Workflow</h5>Size exclusion chromatography (SEC) is typically used after affinity purification to further improve protein purity. Following elution with imidazole or glutathione, desalting is required to prevent buffer components from interfering with downstream assays. This is often achieved using desalting columns such as G-25 or PD-10.To remove lower-molecular-weight contaminants, finer SEC media—such as Superdex or Sephacryl columns—are employed. Concentration steps using molecular-weight cut-off filters are then applied to obtain the desired protein concentration for functional studies.These iterative purification and troubleshooting steps are a routine part of protein biochemistry and reflect the importance of methodical optimization and careful validation.<h5>The Role of Mass Spectrometry in Biomolecular Characterization</h5>Mass spectrometry is a key analytical tool in Subhoja’s research pipeline, particularly for target identification and validation. In both malaria and cancer research, MS is used alongside chromatography, immunoprecipitation, and pull-down assays to study protein interactions and molecular recognition events.Affinity-based mass spectrometry enables the identification of binding partners and interactors, whether studying proteins, long non-coding RNAs, or protein complexes. Techniques such as native MS, tandem affinity purification, and proximity labeling (e.g., TurboID-based workflows) provide deeper insights into molecular networks and signaling pathways.These approaches are essential for understanding how candidate drug targets function within complex biological systems.<h5>Sample Preparation Challenges in Biological Research</h5>Sample preparation remains one of the most challenging aspects of biological experimentation. Whole-cell lysates contain proteases, nucleases, and other components that can rapidly degrade target molecules. Preventing degradation requires minimizing preparation time, maintaining low temperatures, and using appropriate inhibitor cocktails.Reproducibility is also critical: biological experiments require multiple replicates, and variability is often unavoidable. Careful handling, protocol optimization, and continuous troubleshooting are essential to ensure reliable results, whether preparing samples for chromatography, mass spectrometry, sequencing, or immunoprecipitation.<h5>Advances in Chromatography and MS for Malaria Research</h5>Modern advances in chromatography and mass spectrometry significantly enhance malaria research by enabling precise target identification, quantification, and functional characterization. Drug discovery workflows begin with construct design and recombinant expression, followed by purification and interaction studies.In malaria research, stage-specific parasite biology requires careful extraction and analysis of proteins from different life cycle stages. Tandem affinity MS, immunoprecipitation, and in vivo validation studies help confirm target relevance and therapeutic potential.Recent work on repurposed kinase inhibitors has shown promising results, including inhibition of hemozoin formation—a key detoxification pathway for the malaria parasite—highlighting the potential of such compounds for further development.<h5>Malaria, Drug Resistance, and Global Impact</h5>Malaria remains a major global health burden, with over 600,000 deaths annually and widespread drug resistance complicating treatment. Artemisinin resistance, particularly associated with mutations in the K13 propeller domain, has driven the search for new targets and therapies.During her PhD, Subhoja focused on falcipain-2, a cysteine protease involved in hemoglobin degradation within the parasite. This pathway is critical for parasite survival and has emerged as a promising drug target. Her work revealed that falcipain-2 operates within a larger protein complex responsible for hemoglobin processing and amino acid release.Understanding these molecular mechanisms is essential for developing robust, stage-specific antimalarial strategies.<h5>Advice for Early-Career Researchers</h5>For researchers just starting out, Subhoja emphasizes the importance of hands-on experience. Working directly with cells, lysates, and analytical tools is essential for truly understanding experimental systems. Failure is an inherent part of research, and perseverance is key.Motivation, teamwork, careful sample handling, and thorough preparation all contribute to long-term success. Reading extensively, critically evaluating one’s own work, and appreciating incremental progress are vital aspects of a sustainable research career.Every successful experiment—no matter how small—represents meaningful progress and contributes to the broader goals of science and medicine.<h5>Closing Remarks</h5>The discussion highlights how interdisciplinary approaches combining chromatography, mass spectrometry, structural biology, and biochemistry are driving advances in malaria drug discovery. Through careful experimental design, analytical rigor, and collaborative teamwork, researchers can address complex biological challenges and contribute to global health solutions.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Affinity, Gel Filtration, Size Exclusion Chromatography: Repurposing Kinase Inhibitors for Malaria

In the week of February 9, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 000 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. SelectScience: High-Throughput Stability Screening Strategies for Antibody Formulation</h5><ul><li>Tu, 10.2.2026 17:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5807">Registration</a></li></ul>Learn how high-throughput DLS/SLS and rapid-screening DSC accelerate stability assessment of high-concentration antibody formulations, enabling faster, data-driven biologics development.<h5>2. Phenomenex: Big Scale, Big Wins – Prep Chromatography Explained</h5><ul><li>We, 11.2.2026 10:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5793">Registration</a></li></ul>Learn how to scale analytical methods to preparative HPLC, optimize loading capacity, and understand the limits of preparative columns for pharmaceutical applications.<h5>3. ALS Czech Republic: PFAS in Food &amp; Food Contact Material</h5><ul><li>We, 11.2.2026 15:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5816">Registration</a></li></ul>Get a practical overview of PFAS in food and food contact materials, including EU and US regulations, key analytical challenges, and reliable PFAS testing strategies.<h5>4. New Food Magazine: The Science of Next-Gen Ingredients – Fermentation, Formulation and Function</h5><ul><li>We, 11.2.2026 16:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5720">Registration</a></li></ul>Explore how fermentation-driven innovation is transforming functional food ingredients and how advanced analytics optimize flavour, functionality, and stability.<h5>5. SCIEX: Accurate Mass Fundamentals – Interpreting and Applying Your Data</h5><ul><li>We, 11.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5772">Registration</a></li></ul>Session 3 focuses on interpreting and applying accurate mass data to confirm compound identity, move beyond basic quantitation, and troubleshoot results for confident reporting.<h5>6. Agilent Technologies: Process Analytical Techniques – Online HPLC for Real-Time Monitoring and Control of Bioprocesses</h5><ul><li>Th, 12.2.2026 06:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5834">Registration</a></li></ul>Discover how PAT HPLC enables near-real-time monitoring of critical quality attributes in bioprocessing, with a case study on charge-variant control by cation-exchange chromatography.<h5>7. Thermo Fisher Scientific: Introducing the Orbitrap Excedion Pro Hybrid MS</h5><ul><li>Th, 12.2.2026 11:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5889">Registration</a></li></ul>Discover the new Orbitrap Exploris Pro with expanded ETD/EThcD capabilities for confident biopharmaceutical characterization, including intact proteins, PTMs, ADCs, and large biomolecules.<h5>8. Waters Corporation: Planning Your NuGenesis Upgrade – Insights and Best Practices for a Smooth Transition</h5><ul><li>Th, 12.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5833">Registration</a></li></ul>Learn how to plan a successful NuGenesis upgrade, transition to Windows 11, and unlock new capabilities such as dashboards for real-time operational insights.<h5>9. Thermo Fisher Scientific: Comprehensive Analytical Strategies for Peptide Therapeutics and GLP-1 Agonists with Agilent</h5><ul><li>Th, 12.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5814">Registration</a></li></ul>Explore analytical workflows for peptide therapeutics, including method development, peptide mapping, GLP-1 QC, and LC-MS strategies across Agilent platforms.<h5>10. Agilent Technologies: Moving from R&amp;D and Limited QC on a UV-Vis-NIR Instrument to Large-Scale QC Using an Autosampler</h5><ul><li>Th, 12.2.2026 20:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/2104">Registration</a></li></ul>This webinar covers practical aspects of adding and using an autosampler to maximize UV-Vis-NIR QC workflows at scale.<h5>11. Agilent Technologies: LC Method Transfer – Hidden Challenges &amp; Absolute Solution</h5><ul><li>Fr, 13.2.2026 06:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5787">Registration</a></li></ul>Discover why LC method transfer between legacy and modern systems is challenging, which hidden parameters affect retention and peak shape, and how to achieve robust, reliable results.

Webinars LabRulezLCMS Week 07/2026

Charge detection mass spectrometry (CDMS) allows direct mass determination of individual ions and is increasingly used to study heterogeneous biological samples. This work demonstrates the use of Orbitrap-based CDMS/Direct Mass Technology (DMT) for quantitative analysis of transthyretin (TTR) tetramer samples below 100 kDa, extending CDMS beyond its traditional qualitative role.DMT resolved wild-type and C-terminally modified TTR homotetramers, as well as hybrid tetramers, enabling kinetic analysis of subunit exchange and stability. The approach also quantified thyroxine binding to TTR variants, revealing differences in binding affinity linked to C-terminal modification. By separating overlapping m/z signals through charge measurement, CDMS enables accurate mass and abundance determination, highlighting its potential for quantitative analysis of complex protein systems.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771">Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology</a></h4>Robert L. Rider, Jared Hampton, Zhenyu Xi, Carter Lantz, Sangho D. Yun, Weijing Liu, Rosa Viner, Arthur Laganowsky, and David H. Russell*Anal. Chem. 2025, 97, 49, 27057–27063<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05771">https://doi.org/10.1021/acs.analchem.5c05771</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.Transthyretin (TTR) is a homotetrameric transport protein that circulates in plasma and cerebrospinal fluid, delivering thyroxine (T4) and retinol-binding protein–vitamin A complexes. <a href="javascript:void(0);">(1)</a> The stability of the TTR tetramer is central to its physiological role because dissociation into monomers can initiate misfolding and amyloid formation, leading to systemic or hereditary transthyretin amyloidosis. <a href="javascript:void(0);">(2)</a> Subunit exchange between wild-type (WT) and variant TTR proteoforms, including disease-associated mutations such as V30M and V122I, have been implicated in amyloid progression by generating hybrid tetramers (tetramers containing WT and mutant subunits) with altered stabilities. <a href="javascript:void(0);">(3,4)</a> Ligand binding, particularly at the two thyroxine-binding sites located at the dimer–dimer interface, can kinetically stabilize the tetramer and modulate amyloidogenicity. <a href="javascript:void(0);">(5,6)</a> Accurate measurement of both subunit exchange kinetics and ligand binding stoichiometry is therefore critical for elucidating the TTR dynamics and stability.Affinity or sequence tags are widely employed in protein expression, purification, or detection. <a href="javascript:void(0);">(7,8)</a> While these tags are often assumed to be inert, their influence on protein structure and dynamics are rarely examined in detail. <a href="javascript:void(0);">(9,10)</a> Protein tags at the N- and C-terminus of TTR have been shown to have differing gas phase stabilities from those of WT-TTR. <a href="javascript:void(0);">(11)</a> The C-terminus is of particular interest because this region participates in the dimer–dimer interface that governs tetramer stability. <a href="javascript:void(0);">(11,12)</a> Characterizing how the C-terminal tag (CT) (-ASGENLFYQ) affects TTR’s solution stability and ligand binding is not only relevant for understanding TTR dynamics but also provides an example of how expression tags can alter protein dynamics. <a href="javascript:void(0);">(13)</a>Native mass spectrometry (nMS) has been invaluable for characterizing protein complexes, <a href="javascript:void(0);">(14)</a> yet conventional nMS often struggles with heterogeneous samples where overlapping charge state distributions and adduct heterogeneity limit resolution and quantitation. <a href="javascript:void(0);">(15)</a> Charge detection mass spectrometry (CDMS) addresses these limitations by independently measuring the charge and m/z of individual ions, enabling the direct determination of molecular mass and abundance. Development of CDMS has largely focused on achieving higher mass resolution <a href="javascript:void(0);">(16)</a> and extending measurements toward assemblies into the GDa range. <a href="javascript:void(0);">(17,18)</a> However, there is untapped utility for CDMS experiments other than mass and proteoform determination. Jordan et al. showed the capability to assess conformational heterogeneity of mAb aggregates using the added charge dimension that CDMS provides. <a href="javascript:void(0);">(19)</a> The current work demonstrates that CDMS can separate proteoforms with overlapping m/z values based on charge and quantify their relative abundances in complex mixtures. While nMS is already a highly quantitative technique, our results establish CDMS as an equally powerful tool for quantitative analysis in heterogeneous systems. <a href="javascript:void(0);">(20,21)</a>Here, we apply Orbitrap-based CDMS/Direct Mass Technology (DMT) using the selective temporal overview of resonant ions (STORI) approach <a href="javascript:void(0);">(22,23)</a> to quantitatively compare WT-TTR and CT-TTR, focusing on two biologically relevant properties: tetramer stability assessed via subunit exchange kinetics and ligand-binding affinity. Conventional nMS cannot fully resolve the overlapping charge states of WT- and CT-TTR or their ligand-bound states. However, DMT can resolve these species by directly measuring the mass (m/z × charge), enabling quantitation of all proteoforms. The data reveal that the CT tag alters tetramer stability and thyroxine-binding affinity, demonstrating the structural sensitivity of TTR to modifications at its C-terminus. More broadly, this work demonstrates the impact that protein tags can have on native protein interactions and highlights the broader utility of quantitative CDMS for probing heterogeneous biological samples.<h4>Experimental Section</h4><h5>Data Collection</h5>All experiments were conducted on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/560">Thermo Scientific Q-Exactive UHMR</a> with added DMT capabilities (Bremen, Germany). Before DMT, mass spectra were collected at various resolving powers (6–200k) for each sample, with the instrument parameters reported in the Supporting Information (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Table S1</a>). For DMT experiments, the trapping gas pressure in the HCD cell was reduced to 0.3–0.8 to attenuate the signal intensity to a single ion level, as well as decreasing the UHV pressure to assist ion retention through the entire transient of Orbitrap analysis. We observed no significant difference between mass spectra collected at various HCD cell pressures (Supporting Information, <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figure S1</a>). For DMT collection, automated ion control (AIC) and 100% target density were used with 200k resolving power.<h4>Results and Discussion</h4>CDMS has emerged as a powerful tool for analyzing heterogeneous biomolecular samples, enabling accurate, direct mass determination by simultaneously measuring the charge and m/z for individual ions. While CDMS has been widely applied for qualitative analyses, its potential for quantitative and less than MDa applications remains underexplored. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>A shows the theoretical mass spectrum of WT-TTR (14+ to 16+) and CT-TTR (15+ to 17+) homotetramers, where the two proteoforms become increasingly resolved as the charge states increase (&lt;3900 m/z). <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>B zooms in on the 14+ (WT) and 15+ (CT) charge states, highlighting their strong overlap, which prevents accurate deconvolution of the proteoforms by conventional methods. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>C displays theoretical distributions for 0, 1, and 2 T4 bound states of both WT- and CT-TTR tetramers, where &lt;3900 m/z has observable separation between all proteoforms. However, for the 14+ and 15+ charge states of WT- and CT-TTR, respectively, the 0 T4- and 1 T4-bound populations overlap (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>D). Furthermore, commonly adducted species (Na+, K+, and Zn2+) observed in experimental spectra broaden these distributions, making it increasingly difficult to distinguish and deconvolute the proteoforms (see <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figure S2</a>). Here, we employ Orbitrap-based CDMS/DMT to overcome this m/z overlap to resolve and quantify hybrid tetramer formation and T4 binding.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2025_97_49_27057_27063_Figure_1_A_Theoretical_mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_47232849d9.jpg" alt="Anal. Chem. 2025, 97, 49, 27057–27063: Figure 1. (A) Theoretical mass spectra of WT-TTR and CT-TTR homotetramers. (B) Zoomed-in view of the 14+ WT-TTR and 15+ CT-TTR distributions to show the large overlap of the proteoforms. (C) Theoretical mass spectra of WT-TTR and CT-TTR homotetramers with thyroxine (T4) binding. (D) Zoomed-in view of the 14+ WT-TTR and 15+ CT-TTR distributions where the 0 and 1 T4 have overlapping distributions. These theoretical distributions do not contain any commonly adducted species (Na+, K+, Zn2+), which broaden the distributions and create more overlap even for the proteoforms in the range 3300–3900 m/z (see Figure S2)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2025_97_49_27057_27063_Figure_1_A_Theoretical_mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_47232849d9.jpg 187w," sizes="100vw" width="1417" height="1182"><h5>Thyroxine Binding to TTR Homotetramers</h5>Thyroxine is the less active form of a thyroid hormone important for metabolism that binds to TTR for transport throughout plasma and cerebral spinal fluid. <a href="javascript:void(0);">(31)</a> Turnover of T4 into T3 (active) occurs after dissociation, where it can then modulate gene expression via binding to nuclear receptors. <a href="javascript:void(0);">(32)</a> The TTR tetramer gains substantial stability as it binds up to 2 T4 at the tetramer interface, decreasing tetramer dissociation and SUE. <a href="javascript:void(0);">(33)</a> This has been shown previously to decrease the amyloidogenic rate of TTR, which led to tafamidis (similar in structure to T4) to be designed and is currently the only drug that is approved for clinical treatment of TTR amyloidosis. <a href="javascript:void(0);">(34)</a> Measuring the difference in binding affinity between TTR proteoforms may provide insight into regions of TTR or TTR intermolecular/intramolecular interactions that are important for binding of small molecules such as tafamidis and T4.DMT was further applied to quantify T4 binding to WT- and CT-TTR homotetramers, highlighting the technique’s utility in probing protein–ligand interactions. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig3">Figure 3</a>A shows a representative mass spectrum of TTR homotetramers in the presence of T4. While ligand-bound species can be observed, homotetramers cannot be confidently resolved across the entire 3000–5000 m/z range. By leveraging the charge-resolving capabilities of DMT, we achieve separation of the homotetramers (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig3">Figure 3</a>B,C) and the 0, 1, and 2 ligand-bound states. The 2D plot clearly shows the gain in resolution achieved when charge is simultaneously measured with m/z by separating the 14+ and 15+ charge states for WT and CT, respectively, in the range 3900–4200 m/z. Additionally, using ion mobility does not provide the same kind of 2D resolution due to the similarity in arrival times for the homotetramer proteoforms, as evidenced by <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figures S4 and S5</a> (see the Supporting Information). These data provide evidence that when ion mobility is able to separate out species that overlap in m/z yet differ in mobility, CDMS could be an alternative or used complementarily since the species likely also differ in charge.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2025_97_49_27057_27063_Figure_3_A_Mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_with_thyroxine_binding_61b1e98a94.jpg" alt="Anal. Chem. 2025, 97, 49, 27057–27063: Figure 3. (A) Mass spectra of WT-TTR and CT-TTR homotetramers with thyroxine binding. Ligand binding can be resolved, but homotetramers cannot be confidently identified. Charge states labeled are for WT; CT is always one charge state higher at the same m/z range. (B) DMT heatmap resolving WT-TTR and CT-TTR homotetramers with the additional measurement of charge. (C) Deconvoluted mass spectrum from DMT analysis. Both homotetramers and their ligand binding are resolved, and fit for analysis is shown in red. (D) Mole fraction of each homotetramer and their thyroxine binding species. Error bars represent the standard deviation of replicates (n = 3). The significance for each ligand state is in respect to the left adjacent state. *p &lt; 0.05." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2025_97_49_27057_27063_Figure_3_A_Mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_with_thyroxine_binding_61b1e98a94.jpg 181w," sizes="100vw" width="1266" height="1094"><h4>Conclusion</h4>This work demonstrates that quantitatively, Orbitrap-based CDMS/DMT can determine differences in protein-complex stability and ligand binding. By directly comparing WT- with CT-TTR, we show that the CT tag accelerates tetramer dissociation while enhancing T4 binding affinity. These results indicate that the C-terminus, located at the dimer–dimer interface, plays a more significant role in TTR stability and ligand recognition than previously appreciated. <a href="javascript:void(0);">(12)</a> Even the addition of a short peptide sequence perturbs noncovalent interactions at the interface, likely altering solvent accessibility, and the dynamics of the thyroxine binding channel. <a href="javascript:void(0);">(37,54)</a> Such findings underscore the importance of evaluating how seemingly minor sequence modifications, such as affinity tags, can influence fundamental biophysical properties.Beyond TTR, this work positions quantitative CDMS as a broadly applicable strategy for analyzing heterogeneous protein systems, where charge domain separation overcomes the resolution limits of m/z domain measurements in traditional nMS experiments. While much of the field has emphasized extending CDMS to ultrahigh masses and maximal resolution, <a href="javascript:void(0);">(16,18)</a> our results highlight the underexplored potential of applying the method in the 1000–10,000 m/z range common to nMS experiments. This capability is directly relevant to heterogeneous membrane protein complexes, which often display broad distributions of oligomeric states, PTMs, lipid, and ligand adducts that complicate spectra. <a href="javascript:void(0);">(48,55)</a> Similarly, mAbs can oligomerize and exhibit mass heterogeneity from variable glycosylation, affecting pharmacokinetics, effector function, and stability. <a href="javascript:void(0);">(19)</a> CDMS may resolve and quantify such proteoforms in a single experiment without the need for charge reduction or chemical derivatization. <a href="javascript:void(0);">(48,56,57)</a>

Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology

Article

Webinars

Video

Scientists

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

The Analytical Scientist

Agilent Technologies

Technology Networks

Phenomenex

Thermo Fisher Scientific

SelectScience

SCIEX

Waters Corporation

In this virtual Ask Me Anything session we are offering you a chance to delve into the fascinating world of PFAS (Per- and Polyfluoroalkyl Substances).
We are honored to present Dr. Carol Kwiatkowski, a distinguished science and policy senior associate from Green Science Policy, as our esteemed guest.
Dr. Kwiatkowski will be your guide, providing expert insights and answering all your questions about PFAS. From its profound health and environmental concerns to the ever-evolving landscape of regulations, restrictions, and detection techniques. No question is off limits! 
During this session, you can expect to:
<ul>
<li>Engage in a Live Q&amp;A: Seize the opportunity to directly interact with Dr. Kwiatkowski, posing your most thought-provoking questions, and receive real-time, well-informed answers.
</li>
<li>Gain Expert Perspectives: Immerse yourself in a vibrant exchange of ideas, as Dr. Kwiatkowski shares her profound insights on questions posed by fellow participants.
</li>
</ul>
<blockquote>
Presenter: Dr. Carol Kwiatkowski (Adjunct Assistant Professor, North Carolina State University)
</blockquote>

Technology Networks: Ask Me Anything: PFAS

Ask Me Anything: PFAS

Delve into the fascinating world of PFAS.

<h4>Accelerate time to outcome and achieve efficiency in your laboratory</h4>
Contaminations can enter the food-chain at various stages. This has led to more rigorous regulations for the testing of contaminants in exported, imported, and domestic food and beverages.
In this webinar series, we will discuss how our latest solutions meet industry demands, such as high throughput, enhanced sensitivity requirements, increased accuracy, and compliance.
<h4>Episode 2: Solving challenges in the determination of pyrrolizidine alkaloids via LC-MS/MS and LC-IM-HRMS</h4>
With the increasing demand for food and more rigorous regulations, there is more pressure for laboratories to operate efficient, sensitive, and selective analysis methods.
Amongst various food toxins, analysis of plant alkaloids is a prerequisite nowadays. This of course, presents multiple challenges for testing laboratories.
During this session we will discuss:
<ul>
<li>Can critical pairs of isomers of Pyrrolizidine alkaloids be chromatographically separated?
</li>
<li>What efficient clean-up strategies can be utilized to remove matrix co-extractives?
</li>
<li>Can techniques like ion mobility be utilized to separate isomers?
</li>
</ul>
Join us for the food safety webinar series, where you can gain insights from industry experts and ask your questions in our live Q&amp;A session. We are really looking forward to discussing this topic further with you.
<blockquote>
Presenter: Nicola Dreolin (Senior Scientist and Product Manager, Waters Corporation)
</blockquote>
<blockquote>
Nicola Dreolin is a Senior Scientist and Product Manager at Waters. Nicola is specialised in method development for a variety of applications in food, environmental and life sciences. During the past five years, he was involved in different research projects regarding metabolomics, ion mobility and direct-mass spectrometry. Before joining Waters, Nicola worked as an Analytical Scientist at Elements, where he developed targeted and screening methods for the analysis of extractables and leachables, pharmaceuticals, tobacco and agrochemicals.
</blockquote>
<blockquote>
Presenter: Laura Carbonell Rozas (Postdoctoral Researcher, University of Almeria (Spain))
</blockquote>
<blockquote>
Laura Carbonell Rozas is a Postdoctoral researcher at the University of Almeria (Spain), within the research group “Analytical Chemistry of Contaminants”. Over the past seven years, Laura has been working on developing novel strategies for the determination of a wide range of food and environmental contaminants, including mycotoxins and alkaloids. In her research, Laura also pioneered the investigation of “greener” alternatives to conventional sample preparation methods. She obtained her PhD in Analytical Chemistry at the University of Granada (Spain) and she has worked with multiple international organisations, including LABERCA (France), CONICET (Argentina), and the University of Parma (Italy).
</blockquote>

Waters Corporation: Solving challenges in the determination of pyrrolizidine alkaloids via LC-MS/MS and LC-IM-HRMS

Solving challenges in the determination of pyrrolizidine alkaloids via LC-MS/MS and LC-IM-HRMS

How our latest solutions meet industry demands, such as high throughput, enhanced sensitivity requirements, increased accuracy, and compliance.

Pyrrolizidine alkaloids via LC-MS/MS and LC-IM-HRMS

Per- and polyfluoroalkyl substances (PFAS), also referred to as ‘forever chemicals’, are an increasing concern since they accumulate in the environment and may have some deleterious effects on human health.
In this webinar, Dr. Estelle Riche, Global Application Specialist from Merck KGaA, Darmstadt, Germany, will discuss the importance of reagent water quality in trace analyses of PFAS by LC-MS/MS. Dr. Riche will show data on the efficiency of a lab water purification system at removing traces of PFAS from tap water and delivering ultrapure water suitable for sensitive PFAS testing. This webinar will also offer guidance on how to select an optimal water purification solution for these analyses, including tips on how to prevent water contamination for optimal experimental results.
Key learning objectives
<ul>
<li>Understand the role of reagent water in PFAS analyses by LC-MS/MS
</li>
<li>Discover how water purification technologies play a role in PFAS removal
</li>
<li>Learn how to select the best water purification solution to suit your lab’s needs
</li>
</ul>
Who should attend?
<ul>
<li>Any scientist analyzing or planning to analyze PFAS
</li>
<li>Lab managers and anyone using or maintaining lab water purification systems
</li>
</ul>
<blockquote>
Presenter: Dr. Estelle Riche, PhD (Global Application Specialist, Merck KGaA, Darmstadt, Germany)
</blockquote>
<blockquote>
Dr. Estelle Riche holds an engineering degree in chemistry from ESCOM in France and a Ph.D. in chemistry from the University of North Carolina (UNC) in the USA. She started her career as a Professor at UNC, then joined Merck KGaA, Darmstadt, Germany eighteen years ago. She is currently Global Application Specialist for Lab Water Solutions and her responsibilities include understanding the potential impact of water quality on the results of laboratory analyses.
</blockquote>
<blockquote>
Presenter: Carrie Haslam (SelectScience)
</blockquote>
<blockquote>
Dr. Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Materials Science, Alzheimer’s disease and Clinical Diagnostics. Carrie completed a Ph.D. from The University of Plymouth, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.
</blockquote>

SelectScience: Is your lab water pure enough for sensitive PFAS analyses?

Is your lab water pure enough for sensitive PFAS analyses?

The importance of reagent water quality in trace analyses of PFAS by LC-MS/MS.

Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!
Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. 
We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. 
Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. 
The event will have three parts: 
<ul>
<li>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).
</li>
<li>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).
</li>
<li>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).
</li>
</ul>
<blockquote>
Presenter: Day Powell (Environmental Application Specialist , Agilent)
</blockquote>
<blockquote>
Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.
</blockquote>
<blockquote>
Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).
</blockquote>
<blockquote>
Presenter: Marcus Chadha (EMEA Applications Specialist Manager, Agilent) Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.
</blockquote>
<blockquote>
In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.
</blockquote>
<blockquote>
He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.
</blockquote>
<blockquote>
Presenter: Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)
</blockquote>
<blockquote>
Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.
</blockquote>
<blockquote>
His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.
</blockquote>
<blockquote>
Presenter: Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)
</blockquote>
<blockquote>
Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.
</blockquote>
<blockquote>
Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.
</blockquote>
<blockquote>
She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.
</blockquote>

Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

The development and expansion of analytical methods for per- and polyfluoroalkyl substances (PFAS) in food is essential for the continued monitoring of the United States (US) food supply and assessments of dietary intake.
In March of 2022, the European Union Reference Laboratory (EURL) for halogenated persistent organic pollutants (POPs) in Feed and Food released a guidance document covering priority PFAS of interest, including analytical method parameters and limits of quantification (LOQs). As a result, the Food and Drug Administration (FDA) began method extension work to incorporate ten new additional analytes to method C-010.02 including long chain perfluorosulfonic acids, fluorotelomer sulfonates, and perfluorooctane sulfonamide. In December of 2022, The European Union published Commission Regulation 2022/2388, establishing maximum levels for perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorohexane sulfonic acid (PFHxS) in certain foodstuffs, primarily fish, molluscs, crustaceans, and eggs. As a result, the FDA method was evaluated for performance in reaching EU required LOQs for both compliance and monitoring purposes. The FDA method was found to be able to reach all required LOQs for analytes in matrices with established maximum levels and with further method modifications, required LOQs could be met in fruits, vegetables, and milk.
Key Learning Points:
<ul>
<li>Understand the FDA’s approach for PFAS LOQs in various food matrices
</li>
<li>Learn about the EU reference lab guidance for PFAS in foods and how the FDA is taking a similar approach to food safety
</li>
<li>Take a deep dive into which PFAS are designated targets and which are being monitored for screening
</li>
</ul>
Who Should Attend:
<ul>
<li>Any scientists, lab analysts, food safety advocates, food manufacturers or anyone interested in food safety.</li>
</ul>
<blockquote>
Presenter: Susan Genualdi Ph.D. (Research Chemist, Food and Drug Administration)
</blockquote>
<blockquote>
Susan Genualdi is currently a Research Chemist in the Center for Food Safety and Applied Nutrition at the Food and Drug Administration. Her research over the last 12 years has focused on developing methods for the analysis of direct and indirect food additives in food and food packaging and for the last 6 years has focused on PFAS analysis in foods. Prior to her work at the FDA, she received her PhD in Analytical Chemistry at Oregon State University and was a postdoctoral fellow at Environment Canada.
</blockquote>
<blockquote>
Presenter: Richard F. Jack Ph.D. (Global Market Development Manager, Phenomenex)
</blockquote>
<blockquote>
Richard F. Jack, Ph.D. Richard is the Global Market Development manager for the environmental and food markets at Phenomenex corporation. He has over 18 yrs. experience with chromatography and mass spectrometry for the environmental, semiconductor, chemical, and pharmaceutical industries. Richard is a former EPA Scientific Advisor for the EPA’s panel on Hydraulic Fracturing, a coauthor for EPA 557 and 557.1 along with ASTM D8001 and updates to D4327 and D6919 methods. He is currently the Second Vice Chairman for the ASTM D19 subcommittee on water analysis. Richard received his Ph.D. in biochemistry and anaerobic microbiology from Virginia Tech University and Master’s in ecology from the University of Tennessee.
</blockquote>

Phenomenex: FDA’s Analytical Method for PFAS Detection

FDA’s Analytical Method for PFAS Detection

Understand the FDA’s approach for PFAS LOQs in various food matrices.

Typical PFAS methods include 18 to 40 individual legacy, short to long chain PFAS compounds. However, as the long chain PFAS have been phased out of industrial uses, they were replaced by short and ultra-short chain versions with similar chemistries, environmental persistence, and toxicological impact. As we continue to assess PFAS impacts in the environment, methods for identifying and quantifying the short and ultra-short chain PFAS are also needed.
Chromatography methods using common reverse phase columns, however, do not retain the ultra-short chain PFAS, so these are not usually included in the current quantitative methods.
We will explore how we can take advantage of the mixed mode chemistry of PFAS molecules to routinely detect and quantify a broad scope of PFAS, including the ultra-short chains to legacy long chain versions, all detected in a single injection, using mixed mode reverse phase and anion exchange separation column chemistries.
<h3>Key Learning Topics:</h3>
<ul>
<li>Improved workflow for a wide range of PFAS compounds</li>
<li>Mixed mode separations using a reverse phase and anion exchange column</li>
<li>Improved analyte identification and data quality</li>
<li>Addressing instrument contamination</li>
</ul>
<h5>Who should attend?</h5>
<ul>
<li>PFAS Program Managers</li>
<li>Laboratory Managers</li>
<li>Scientists</li>
<li>Quality Assurance Managers</li>
</ul>
For more information please contact Jenifer_Lewis@Waters.com or Ravali_Alagandula@Waters.com
<blockquote>
Presenter: Kari Organtini, PhD (Principal Scientist, Waters Corporation)
</blockquote>
<blockquote>
Kari Organtini is a Principal Scientist at Waters Corporation and has been with the company for six years. She received her PhD from Penn State University in 2015 studying the occurrence of dioxins and furans in fire debris and their implications to first responder health. At Waters, Kari is part of the food and environmental applications team. During her career, Kari has developed applications using both LC and GC techniques for a variety of applications ranging from pesticides to persistent organic pollutants. She is currently the scientific lead for developing PFAS applications at Waters.
</blockquote>

LabRulez/AI: To Isolation and Beyond: A New Mixed Mode Column Approach for PFAS Chromatography

To Isolation and Beyond: A New Mixed Mode Column Approach for PFAS Chromatography

We will explore how we can take advantage of the mixed mode chemistry of PFAS molecules to routinely detect and quantify a broad scope of PFAS.

A New Mixed Mode Column Approach for PFAS Chromatography

Whether you are analyzing for food contaminants such as PFAS or pesticide residues, screening for food adulteration in tea, or profiling the flavor of alternative proteins, trusted answers is critical in food testing. Agilent keeps you at the forefront of the latest trends in food testing – so you can deliver the highest quality and value to your customers. Join us in this webinar series as food testing experts from all over the world talk share their robust and reliable workflow solutions to meet the challenges in food safety, authenticity, and quality testing. These experts have allotted ample time for discussion so share your thoughts and bring in your questions!
The webcast will take the audience through the suite of analytical techniques that were utilized to obtain a comprehensive picture of the presence of per-and polyfluoroalkyl substances (PFAS) in selected Canadian food packaging used for fast foods. The levels and profiles of PFAS in the samples can provide valuable information on the sources of these chemicals, especially polymeric ones.
Key Learning Objectives/What attendees will learn:
<ul>
<li>Methodological approach for the analysis of PFAS in packaging materials
</li>
<li>PFAS profiles provide information on sources
</li>
<li>Implications for regulatory purposes
</li>
</ul>
<blockquote>
Presenter: Marta Venier, PhD (Assistant Professor, Paul O’Neill School of Public and Environmental Affairs, Indiana University)
</blockquote>
<blockquote>
Marta Venier is an environmental chemist and Assistant Professor at the Paul O’Neill School of Public and Environmental Affairs at Indiana University in Bloomington, Indiana. In her research she employs analytical chemistry and mass spectrometry techniques to study the fate, transport, and behavior of persistent organic pollutants including both legacy and emerging pollutants in the indoor and outdoor environment and in consumer products. Since November 2019, she has been leading the Integrated Atmospheric Deposition Network (IADN), a monitoring program funded by the U.S. Environmental Protection Agency.
</blockquote>

Agilent Technologies: PFAS in Fast Food Packaging

PFAS in Fast Food Packaging

The suite of analytical techniques that were utilized to obtain a picture of the presence of PFAS in selected Canadian food packaging used for fast foods.

Are you ready to propel drug development and revolutionize the pharma industry?
On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.
Discover new possibilities:
Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.
Why attend?
<ul>
<li>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field
</li>
<li>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence
</li>
<li>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry
</li>
<li>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5>11:20 - 11:30 Break</h5>
<h5>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5>12:50 - 13:00 Final notes</h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
Presenter: Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)
</blockquote>
<blockquote>
Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.
</blockquote>
<blockquote>
Presenter: Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)
</blockquote>
<blockquote>
Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.
</blockquote>
<blockquote>
Presenter: Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)
</blockquote>
<blockquote>
Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.
</blockquote>
<blockquote>
Presenter: Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)
</blockquote>
<blockquote>
Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.
</blockquote>
<blockquote>
Presenter: Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)
</blockquote>
<blockquote>
Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.
</blockquote>
<blockquote>
Presenter: Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)
</blockquote>
<blockquote>
Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.
</blockquote>
<blockquote>
Presenter: Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)
</blockquote>
<blockquote>
Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.
</blockquote>
<blockquote>
Presenter: Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)
</blockquote>
<blockquote>
Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.
</blockquote>

Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

Are you ready to propel drug development and revolutionize the pharma industry?
On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.
Discover new possibilities:
Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.
Why attend?
<ul>
<li>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field
</li>
<li>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence
</li>
<li>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry
</li>
<li>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology
</li>
</ul>
<h3>Agenda Day 2: Thursday, October 26</h3>
<h5>10:00 - 10:40 Case studies from bioanalytical lab in DMPK, Syngene: SCIEX 7500 system and beyond</h5>
<ul>
<li>Ashwani Gaur (Syngene International Ltd)</li>
</ul>
<h5>10:40 - 11:20 Challenges in quantification of NDSRI’s</h5>
<ul>
<li>Dama Venugopal Rao (Dr. Reddy&#39;s Laboratories)</li>
</ul>
<h5>11:20 - 11:30 Break</h5>
<h5>11:30 - 12:10 Nitrosamine impurities in dermal products: from APIs and their salts (secondary amines) evaluations through analytical chemistry and mass spectrometry</h5>
<ul>
<li>Emiliano de Dominicis (Merieux)</li>
</ul>
<h5>12:10 - 12:50 Extractables and leachables assessments in biologics manufacturing</h5>
<ul>
<li>Lukas Mogler (Lonza)</li>
</ul>
<h5>12:50 - 13:00 Final notes</h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
Presenter: Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)
</blockquote>
<blockquote>
Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.
</blockquote>
<blockquote>
Presenter: Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)
</blockquote>
<blockquote>
Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.
</blockquote>
<blockquote>
Presenter: Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)
</blockquote>
<blockquote>
Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.
</blockquote>
<blockquote>
Presenter: Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)
</blockquote>
<blockquote>
Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.
</blockquote>
<blockquote>
Presenter: Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)
</blockquote>
<blockquote>
Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.
</blockquote>
<blockquote>
Presenter: Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)
</blockquote>
<blockquote>
Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.
</blockquote>
<blockquote>
Presenter: Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)
</blockquote>
<blockquote>
Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.
</blockquote>
<blockquote>
Presenter: Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)
</blockquote>
<blockquote>
Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.
</blockquote>

Pharma conclave 2023 (Day 2)

Developing targeted LC-MS/MS work to quantify key membrane receptors and antigens to evaluate drug targets and the effect of biotherapeutics is extremely challenging.
The expression levels of these proteins are often exceptionally low, the properties of these membrane proteins can limit the effectiveness of extraction and recovery, and the noises from biological matrices are typically high. Traditional methods often suffer from insufficient sensitivity and quantitative accuracy.
The focus of this webinar is to introduce an alternative method designed to implement more generic sample preparation steps in combination of strategic trap-elute chromatography, FAIMS selectivity, and sensitive LC-MS/MS acquisition utilizing selected reaction monitoring (SRM) on a premier triple quadrupole mass spectrometer. Prof. Qu and his team will demonstrate confident quantitation of various membrane receptors and antigens that are important to the biotherapeutics. The presented workflow will also demonstrate advantages to streamlining method development to increase productivity.
<blockquote>
Presenter: Prof. Jun Qu (Assistant Professor, State University New York (SUNY) Buffalo)
</blockquote>
<blockquote>
Jun Qu is a professor in the Department of Pharmaceutical Sciences of SUNY-Buffalo, and the director of Proteomics and Pharmaceutical Analysis Group in NY Center of Excellence in Life Sciences. His research is focused on the study of Clinical/Pharmaceutical Proteomics and Pharmaceutical Analysis by developing novel LC/MS-based strategies to markedly enhance the sensitivity, specificity, throughput and accuracy/precision for protein analysis in highly complex biological matrices. His research programs include i) highly sensitive and accurate characterization of biotherapeutics, targets and markers in pharmaceutical and clinical systems; ii) precise and large-scale global quantification of pathological proteomes using a novel MS1-based proteomic pipeline (IonStar); iii) sensitive identification, localization and quantification of post-translational modifications in tissue proteomes; iv) targeted investigation of marker proteins that are of high interests for clinical and pharmaceutical investigations. Qu lab is also one of the world leaders in LC-MS-based characterization of biotherapeutics in pre-clinical models. He has around 130 peer reviewed publications and &gt;70 grants funded as the principal investigator or co-investigator.
</blockquote>

Thermo Scientific: A new approach to perform ultra-sensitive, accurate, and absolute quantification of key membrane receptors and antigens in tissue and on cell surfaces

A new approach to perform ultra-sensitive, accurate, and absolute quantification of key membrane receptors and antigens in tissue and on cell surfaces

An alternative method designed to implement more generic sample preparation steps in combination of trap-elute chromatography, FAIMS and LC-MS/MS.

LCMS webinars focusing on LC/QQQ - page 19